ARIH2OS: A Potential Drug Target and Biomarker (G646450)

Target Name: ARIH2OS

NCBI ID: G646450

ARIH2OS

ARIH2OS: A Potential Drug Target and Biomarker

ARIH2OS (Ariadne-2 homolog opposite strand protein) is a protein that is expressed in various tissues and cells of the human body. It is a member of the Ariadne family of proteins, which are known for their ability to interact with double-stranded DNA . In this article, we will discuss the potential implications of ARIH2OS as a drug target or biomarker.

The Ariadne Family of Proteins

The Ariadne family of proteins is characterized by the presence of a nucleotide-binding domain (NBD) and a non-histone-like domain (NHD). The NBD is responsible for the protein's ability to interact with double-stranded DNA, while the NHD is involved in the regulation of gene expression and cell signaling.

ARIH2OS is a member of the Ariadne family of proteins and is expressed in various tissues and cells of the human body. It is a 21-kDa protein that is characterized by the presence of a NBD and an NHD. The NBD of ARIH2OS is composed of a single domain that contains a nucleotide-binding domain and a non-histone-like domain.

The NBD of ARIH2OS is unique in that it contains a specific sequence that is highly conserved across various species. This conservation suggests that ARIH2OS may have been evolutionarily conserved to ensure its survival and stability in various cellular and tissue environments.

ARIH2OS Functions as a Protein

ARIH2OS is involved in various cellular processes that are essential for cell survival. One of its functions is to regulate DNA replication and repair. ARIH2OS is known to interact with the double-stranded DNA complex, which includes the DNA replication machinery. This interaction is critical for the proper functioning of DNA replication and repair.

ARIH2OS is also involved in the regulation of cell signaling pathways. It has been shown to play a role in the regulation of cell apoptosis, which is a critical process that helps cells remove damaged or dysfunctional proteins.

ARIH2OS as a Drug Target

The potential use of ARIH2OS as a drug target is based on its involvement in various cellular processes that are important for human health. One of the main targets of ARIH2OS is the regulation of cell apoptosis.

ARIH2OS has been shown to play a role in the regulation of cell apoptosis by activating the B-cell lymphoma 1 (Bcl-2) gene. Bcl-2 is a protein that has been shown to promote cell survival by inhibiting the formation of cell apoptosis . By activating Bcl-2, ARIH2OS has been shown to promote the survival of cancer cells.

Another potential target of ARIH2OS is the regulation of cell signaling pathways. It has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of various cellular processes, including cell signaling, inflammation, and metabolism.

ARIH2OS as a Biomarker

The potential use of ARIH2OS as a biomarker is based on its unique expression patterns in various tissues and cells of the human body. ARIH2OS is expressed in various tissues, including the brain, heart, and kidneys, and has been shown to play a role in the regulation of cellular processes that are important for human health.

One of the potential applications of ARIH2OS as a biomarker is its ability to serve as a protein biomarker for various diseases, such as cancer, neurodegenerative diseases, and cardiovascular diseases. The unique expression patterns of ARIH2OS in these diseases make it an attractive candidate for use as a diagnostic or therapeutic biomarker.

Conclusion

In conclusion, ARIH2OS is a unique and

Protein Name: ARIH2 Opposite Strand LncRNA

The "ARIH2OS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARIH2OS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets